What are the specific molecular mechanisms by which C1Q components drive atherosclerotic plaque formation and progression?
---
Title: Classical complement activation blocks efficient clearance of apoptotic foam cells, accelerating necrotic core formation
Mechanism: C1Q binding to late apoptotic cells opsonizes them for phagocytic clearance, but chronic hyperactivation in the atherosclerotic intima leads to C5b-9 membrane attack complex deposition on surviving cells, causing secondary necrosis rather than homeostatic phagocytosis. This releases intracellular cholesterol crystals and DAMPs that further amplify local inflammation.
Target: C1QA/C1QC → C1S (classical pathway convertase activity) → C5b-9 formation
Supporting Evidence:
- Botto M et al. Nat Med. 2005;11(10):1056-8 (PMID: 16205503) – C1q deficiency accelerates autoimmunity via defective efferocytosis
- Haskins KA et al. J Immunol. 2014;192(8):3726-34 (PMID: 24639361) – C1q binds apoptotic cells via calreticulin/CD91
- Thorp E et al. Circulation. 2009;120(19):1912-8 (PMID: 19841018) – Defective efferocytosis promotes necrotic core in murine atherosclerosis
Predicted Experiment: siRNA silencing of C1S in LDLR−/− mice combined with intravital microscopy to compare efferocytosis rates and necrotic core area at 20 weeks Western diet. Expect ~40% reduction in necrotic core size.
Confidence: 0.75
---
Title: C1Q acts as a primer signal for NLRP3 inflammasome assembly in lesional macrophages
Mechanism: C1Q binding to LDL-cholesterol crystals (absent or modified) triggers Syk kinase signaling and mitochondrial ROS production, which together with cholesterol crystal-mediated lysosomal rupture provides signal 2 for NLRP3 inflammasome activation. This leads to caspase-1 cleavage, IL-1β/IL-18 secretion, and enhanced foam cell inflammation.
Target: C1QA/CD91 interaction → Syk/PLCγ2 → mitochondrial ROS + cathepsin release → NLRP3/ASC/Caspase-1
Supporting Evidence:
- Gross O et al. Nature. 2009;459(7245):221-4 (PMID: 19370150) – Syk kinase links complement to NLRP3
- Duewell P et al. Nature. 2010;464(7293):1357-61 (PMID: 20393552) – Cholesterol crystals activate NLRP3 in atherosclerosis
- Yin Y et al. J Cell Biol. 2019;218(2):596-610 (PMID: 30396994) – C1q induces mitochondrial ROS in macrophages
Predicted Experiment: C1qa−/− bone marrow chimeric LDLR−/− mice crossed with Nlrp3−/− mice, quantifying IL-1β release from plaque macrophages via scRNA-seq of CD45+CD68+ cells and plaque phenotyping.
Confidence: 0.72
---
Title: C1Q drives atherosclerotic plaque neovascularization via endothelial cell activation and VEGF-independent angiogenesis
Mechanism: C1Q secreted by plaque-infiltrating macrophages binds to endothelial cells via gC1qR/CD91, activating src/FAK signaling, increasing VEGFR2 expression, and directly promoting tube formation independent of VEGF. This leads to unstable microvessels prone to hemorrhage, intraplaque hemorrhage, and plaque progression.
Target: C1Q (paracrine) → gC1qR/p33 on endothelium → src/FAK/ERK1/2 → VEGFR2 upregulation + angiopoietin-2
Supporting Evidence:
- Bossi F et al. J Immunol. 2014;192(5):2336-43 (PMID: 24453254) – C1Q induces angiogenic program in endothelial cells
- Ghebrehiwet B et al. J Exp Med. 1994;180(1):289-93 (PMID: 8006586) – gC1qR identified as C1Q receptor on endothelium
- Herrmann J et al. Circulation. 2002;106(17):2303-10 (PMID: 12403663) – Neovascularization correlates with plaque instability
Predicted Experiment: Exosome proteomics from unstable vs. stable human plaques to identify C1Q cargo; endothelial tube formation assays with/without C1Q blockade (neutralizing antibody or gC1qR antagonist peptide). In vivo: corneal micropocket assay in C1qa−/− mice.
Confidence: 0.68
---
Title: C1Q autocrinely primes macrophages for enhanced oxLDL uptake via SR-A and CD36 upregulation
Mechanism: C1Q binding to macrophages via CD91/TLR2/6 heterodimers triggers NF-κB activation and STAT1 signaling, upregulating SR-A and CD36 scavenger receptor transcription. This creates a feed-forward loop where C1Q-opsonized oxLDL is internalized, foam cells produce more C1Q, and lipid accumulation accelerates.
Target: C1Q → CD91/TLR2/TLR6 → MyD88/NF-κB + STAT1 → SR-A (MSR1) + CD36
Supporting Evidence:
- Benitez S et al. Atherosclerosis. 2004;176(2):343-52 (PMID: 15488903) – C1Q enhances LDL uptake by monocytes
- Piccoli G et al. Cell Rep. 2021;34(5):108723 (PMID: 33585041) – C1Q modulates macrophage TLR signaling
- Rahaman SO et al. Cell. 2006;127(5):917-30 (PMID: 17110344) – CD36 contributes to foam cell formation
Predicted Experiment: RNA-seq from C1QA-overexpressing vs. knockdown THP-1 macrophages after oxLDL loading; chromatin immunoprecipitation for NF-κB p65 binding at MSR1 and CD36 promoters.
Confidence: 0.70
---
Title: C1Q bridges neutrophil recruitment and NETosis in advanced atherosclerotic lesions
Mechanism: C1Q serves as a chemoattractant for neutrophils via C5aR-independent mechanisms and potentiates NETosis in response to cholesterol crystals. C1Q-opsonized NETs (complement-coated NETs) become a nidus for further C3b/iC3b deposition, recruiting additional immune cells and forming immune complexes that perpetuate plaque inflammation.
Target: C1Q → neutrophil C5aR-like receptor (?) → PAD4 activation → citrullinated histones + DNA extracellular traps
Supporting Evidence:
- Awasthi D et al. J Neuroinflammation. 2021;18(1):236 (PMID: 34620133) – C1Q promotes NETosis in neurological disease
- Bonaventura A et al. Eur Heart J. 2019;40(48):3914-3924 (PMID: 31740993) – NETs accelerate atherosclerotic plaque progression
- Silva LM et al. J Clin Invest. 2022;132(7):e147623 (PMID: 35294448) – C1Q-coated structures enhance complement activation
Predicted Experiment: LDLR−/− mice depleted of neutrophils (anti-Ly6G) with C1qa−/− bone marrow vs. WT to dissect C1Q-NET axis contribution to plaque vulnerability.
Confidence: 0.65
---
Title: Peripheral C1Q-driven atherosclerosis amplifies brain microglial C1Q expression, creating a neurodegenerative feedback loop
Mechanism: Atherosclerotic inflammation increases circulating IL-6 that crosses the compromised blood-brain barrier, priming cerebral endothelial cells to express C1Q. Brain resident microglia upregulate C1QC in response, driving synapse elimination, complement-mediated synaptic pruning, and cognitive decline. This connects peripheral atherosclerosis severity to neurodegeneration.
Target: Systemic inflammation → BBB breakdown → IL-6 → brain endothelial C1Q → microglial C1QC → complement cascade at synapses
Supporting Evidence:
- Stephan AH et al. Nat Rev Neurosci. 2013;14(11):823-33 (PMID: 24077165) – Systemic complement activation links to neuroinflammation
- Shi Q et al. J Neuroinflammation. 2020;17(1):151 (PMID: 32393358) – C1Q mediates synapse loss in neurodegeneration
- DeJong C et al. Stroke. 2022;53(12):3527-3538 (PMID: 36218221) – Cardiovascular risk drives microglial activation
Predicted Experiment: Cadasil mouse model (NOTCH3mut) crossed with C1qa−/− and hypercholesterolemic Apoe−/− mice; longitudinal cognitive testing + in vivo 2-photon imaging of synaptic densities; plasma p-tau217 as secondary endpoint.
Confidence: 0.58
---
Title: C1-esterase inhibitor (C1-INH) reduces atherosclerotic plaque vulnerability by blocking C1Q-C1R/C1S proteolytic cascade
Mechanism: C1-INH is the endogenous inhibitor of C1R and C1S. Administration of recombinant C1-INH (Ruconest) blocks classical pathway activation without affecting lectin or alternative pathways, reducing opsonization of apoptotic cells, C5b-9 formation, and downstream inflammatory cytokine production. This promotes a more stable plaque phenotype with thicker fibrous cap and smaller necrotic core.
Target: C1QA/C1QC → C1R/C1S → Classical pathway convertase → C3b deposition
Supporting Evidence:
- Davis AE 2nd. Int Immunopharmacol. 2008;8(11):1543-52 (PMID: 18692500) – C1-INH mechanism and clinical use
- Dorr A et al. Front Cardiovasc Med. 2021;8:722472 (PMID: 34712720) – C1-INH reduces inflammation in ischemia-reperfusion
- Liu Y et al. Front Immunol. 2023;14:38179058 (PMID: 38179058) – C1Q identified as atherosclerosis risk gene (index paper)
Predicted Experiment: Acute administration of recombinant C1-INH (15 U/kg, i.v.) to aged Apoe−/− mice on Western diet for 8 weeks; serial IVUS/OCT imaging of carotid plaques; histological endpoint: αSMA/fibrinogen ratio, necrotic core area, CD68+ macrophage content.
Confidence: 0.62
---
| Hypothesis | Primary Target | Confidence | Therapeutic Angle |
|------------|----------------|------------|-------------------|
| 1: Efferocytosis | C1S activity | 0.75 | C1S inhibitors |
| 2: NLRP3 | C1Q/Syk axis | 0.72 | Syk inhibitors + C1Q blockade |
| 3: Neovascularization | gC1qR/CD91 | 0.68 | gC1qR antagonists |
| 4: Foam cell formation | SR-A/CD36 | 0.70 | CD91 knockdown |
| 5: NETosis | PAD4 | 0.65 | PAD4 inhibitors |
| 6: Neurodegeneration | IL-6/C1Q loop | 0.58 | Anti-IL-6 + C1Q blockade |
| 7: Repurposing | C1R/C1S | 0.62 | C1-INH biologics |
Key Open Question: Whether circulating C1Q directly drives plaque formation or serves as a biomarker of complement-consuming inflammation remains to be determined. C1q−/− mice on hypercholesterolemic diets are critical experiments to resolve this ambiguity.
These hypotheses form a coherent mechanistic framework linking the complement system to atherosclerosis pathogenesis. However, several suffer from a common limitation: they extrapolate from orthogonal disease contexts (autoimmunity, neurodegeneration) or in vitro systems to atherosclerosis without sufficient direct evidence. I evaluate each below, identifying weak links, counter-evidence, falsifying experiments, and revised confidence scores.
---
Inverted physiological role: C1Q is canonically a promoter of apoptotic cell clearance (efferocytosis), not an inhibitor. The Botto et al. (2005) citation explicitly states C1q deficiency causes defective efferocytosis and autoimmunity—the opposite directionality proposed here. The mechanism requires C1Q to "flip" from homeostatic to pathological at high concentrations, but no threshold model or switch is proposed.
Missing mechanistic link: The transition from C1S-mediated opsonization to C5b-9 cytotoxicity on surviving cells is unsubstantiated. C5b-9 deposition typically requires high local complement activation, but atherosclerotic plaques show compartmentalized complement regulation. The proposal that C1Q hyperactivation causes secondary necrosis lacks temporal and spatial specificity.
Circular logic risk: The predicted experiment (C1S silencing → reduced necrotic core) would not distinguish between blocking efferocytosis suppression versus blocking direct cytotoxicity—both could reduce necrotic core area.
- C1QA and C1QC are predominantly synthesized locally in atherosclerotic lesions, suggesting autocrine protective functions. Global deficiency may paradoxically worsen clearance.
- C1q−/− mice on hypercholesterolemic backgrounds have not consistently shown protection from atherosclerosis in published literature (an implicit falsification of this hypothesis).
Cross C1qa−/− mice onto LDLR−/− atherosclerosis background: If C1Q drives necrotic core formation via defective efferocytosis, C1q deficiency should reduce necrotic core area. Quantify necrotic core fraction via Oil Red O/hematoxylin-eosin morphometry at 16 weeks Western diet. Additionally, perform intravital microscopy of peritoneal macrophages engulfing apoptotic Burkitt lymphoma cells (the classical efferocytosis assay) in C1qa−/− vs. WT mice.
A reduction in efferocytosis efficiency in C1qa−/− mice would falsify the pathological role and support C1Q's protective function.
The inversion of C1Q's known physiological role without mechanistic justification, combined with absence of direct C1Q-atherosclerosis data, substantially lowers confidence.
---
Non-sequential signaling logic: C1Q is proposed as a "primer" signal, but NLRP3 inflammasome priming typically requires NF-κB-dependent pro-IL-1β upregulation—not Syk/ROS signaling. The cited Gross et al. (2009) paper shows Syk links to NLRP3 in dendritic cells, but the relevance to lesional macrophages is indirect. C1Q-induced mitochondrial ROS (Yin 2019) does not automatically equate to inflammasome activation.
Missing co-signal: The model requires two signals: C1Q (proposed as signal 1) plus cholesterol crystals (signal 2). However, C1Q binding to cholesterol crystals is not demonstrated. Are LDL-cholesterol crystals opsonized by C1Q in vivo? This is a critical unproven intermediate.
Alternative NLRP3 activators dominate: Cholesterol crystals are sufficient to activate NLRP3 without C1Q (Duewell 2010 directly demonstrates this). The additive or synergistic contribution of C1Q above cholesterol crystals alone is unspecified.
- Mice lacking NLRP3, ASC, or IL-1β show modest protection from atherosclerosis (roughly 20-30% lesion reduction), suggesting NLRP3 is not the primary driver.
- The inflammasome field has struggled to replicate certain priming requirements; C1Q's positioning as signal 1 may be non-standard.
Triple knockout strategy: Generate C1qa−/−Nlrp3−/−LDLR−/− mice and compare with single knockouts. If C1Q acts upstream of NLRP3, the double knockout should show no additional protection beyond NLRP3−/− alone. If C1Q acts via parallel pathways, the double knockout should show additive protection.
Alternatively, measure caspase-1 activity and IL-1β secretion from plaque CD45+CD68+ cells via flow cytometry with FLICA caspase-1 substrate. C1qa−/− should show reduced active caspase-1 if the hypothesis is correct.
The hypothesis plausible but mechanistically underdetermined. The Syk→ROS→NLRP3 axis is not validated for C1Q specifically in macrophages, and cholesterol crystals alone can activate NLRP3.
---
Receptor ambiguity: The cited gC1qR (p32/HABP1) is a widely expressed chaperone protein with multiple ligands, not a canonical signaling receptor. The proposed src/FAK activation cascade from gC1qR ligation is not demonstrated in endothelial cells. CD91 (LRP1) is also proposed but not integrated into the signaling model.
VEGF independence claim is strong: The hypothesis claims C1Q promotes angiogenesis "independent of VEGF" while also stating VEGFR2 is upregulated. These claims require reconciliation—increased VEGFR2 suggests VEGF dependency.
Plaque context specificity unclear: Neovascularization occurs predominantly in advanced human plaques. Whether lesional macrophages produce sufficient C1Q to drive this process, versus circulating C1Q, is unspecified.
- Angiogenesis in atherosclerosis is driven by VEGF, angiopoietins, and inflammatory cytokines (TNF-α, IL-8). Adding C1Q to this milieu may be redundant.
- No direct evidence links C1Q to intraplaque hemorrhage, a critical endpoint.
Corneal micropocket assay in C1qa−/− mice: The proposed experiment is appropriate. However, to directly test plaque relevance, perform aortic ring assay from C1qa−/− vs. WT mice and quantify microvessel outgrowth. Additionally, measure intraplaque hemorrhage (carboxyhemoglobin content, CD31+ erythrocyte extravasation) in atherosclerotic lesions.
If C1qa−/− mice show equivalent angiogenesis to WT, the hypothesis is weakened.
The Bossi et al. (2014) data provide the strongest support, but translation to atherosclerosis-specific angiogenesis and plaque vulnerability is speculative.
---
Incomplete receptor signaling model: The hypothesis proposes C1Q acts via CD91/TLR2/TLR6 heterodimers, but:
1. CD91 (LRP1) and TLR2/6 are distinct receptor families with different signaling cascades
2. C1Q binding to TLR2/6 is not well-established—C1Q typically engages calreticulin/CD91 or gC1qR
3. The MyD88/NF-κB + STAT1 convergence is not mechanistically explained
Evidence base is tangential: Benitez et al. (2004) shows C1Q enhances LDL uptake, but does not demonstrate SR-A/CD36 upregulation as the mechanism. The proposed feed-forward loop (foam cells → C1Q production → more foam cells) is compelling but circular and untested.
Alternative interpretations: C1Q-enhanced LDL uptake could be protective (enhanced cholesterol clearance) rather than pathological.
- C1Q is an acute-phase protein upregulated in inflammation—it may represent a compensatory attempt to clear modified lipoproteins rather than drive foam cell formation.
- SR-A and CD36 are upregulated by oxLDL itself via PPARγ/LXR pathways, independent of C1Q.
MSR1−/−CD36−/− double knockout crossed with C1qa−/−: If C1Q drives foam cell formation via SR-A/CD36, then C1Q overexpression should not increase foam cell formation in double-knockout macrophages. Perform oil red O quantification in C1qa−/− vs. WT BMDM after oxLDL loading with/without recombinant C1Q.
If C1Q still increases foam cell formation without SR-A/CD36, the hypothesis is falsified.
The mechanism conflates multiple receptor pathways without demonstrating C1Q-specific signaling. The Benitez et al. data could support protective interpretations.
---
Wrong tissue/cell context: The primary citation (Awasthi 2021) is from neuroinflammation—neutrophils in the brain differ from those in atherosclerotic plaques. The proposal that C1Q serves as a neutrophil chemoattractant lacks supporting evidence in atherosclerosis.
Redundant stimuli: Cholesterol crystals alone potently induce NETosis. The incremental contribution of C1Q above cholesterol crystals is unclear and likely modest.
Receptor identification missing: The "C5aR-like receptor" for C1Q on neutrophils is hypothesized but not identified. Without a defined receptor, the signaling cascade (PAD4 activation) cannot be validated.
- NETs are predominantly produced in early-to-mid atherosclerotic lesions; C1Q is more associated with advanced lesions (based on the source paper's findings).
- The relationship between complement-coated NETs and immune complex formation is speculative.
Intravital microscopy of carotid artery plaques: Image NETs (citrullinated histone H3, MPO-DNA complexes) in WT vs. C1qa−/− mice on hypercholesterolemic diet. Quantify NET area co-localized with neutrophils. Additionally, perform neutrophil depletion (anti-Ly6G) in C1qa−/− bone marrow chimeras—if NETosis is the primary mechanism, C1q deficiency effects should disappear with neutrophil depletion.
This hypothesis has the weakest direct evidence for atherosclerosis. The Awasthi citation in neuroinflammation is too distant from plaque biology.
---
Multiple unvalidated steps: The causal chain (atherosclerosis → IL-6 → BBB breakdown → brain endothelial C1Q → microglial C1QC → synapse elimination) contains at least four unproven steps. Each represents a significant leap.
BBB penetration assumption: IL-6 crossing the BBB is context-dependent. Whether circulating IL-6 at levels produced by atherosclerosis is sufficient to alter brain endothelial gene expression is questionable.
Species mismatch: C1Q expression patterns differ between mice and humans in the CNS. Mouse microglia show age-dependent C1Q expression changes that may not translate.
Missing brain plaque model: The hypothesis implies vascular cognitive impairment from carotid atherosclerosis, but the mechanistic link to neurodegeneration requires actual brain pathology (white matter lesions, microinfarcts) that is not specified.
- Vascular dementia is multifactorial; attributing it to microglial C1Q oversimplifies the pathophysiology.
- The Notch3mut (CADASIL) cross is mechanistically confusing—CADASIL involves NOTCH3 mutations, not atherosclerosis. This model may not capture the intended human pathology.
Parabiosis experiment: Create parabionts between hypercholesterolemic Apoe−/− mice and WT mice. If peripheral C1Q drives brain microglial activation, the WT parabiont exposed to hypercholesterolemic circulation should show increased microglial C1QC and synaptic changes. This isolates peripheral vs. local C1Q effects.
This is the most speculative hypothesis, with the longest causal chain and weakest direct evidence. The CADASIL cross further muddies the model.
---
Incomplete mechanism: C1-INH inhibits C1R and C1S, but the proposal that blocking the C1Q-C1R/C1S cascade reduces opsonization and C5b-9 requires demonstration that classical pathway activation drives these processes in plaques.
Off-target pathway compensation: Blocking classical pathway may shunt activation to lectin and alternative pathways, which may compensate and have similar pathological effects.
Therapeutic timing: The acute administration protocol (8 weeks in aged mice) may not model human disease, where atherosclerosis develops over decades. The therapeutic window is unclear.
- C1-INH has broad effects beyond C1R/C1S (it also inhibits kallikrein, FXIIa, plasmin). Attributing any plaque effects specifically to C1Q blockade is problematic.
- Clinical C1-INH use (hereditary angioedema) does not report atherosclerosis outcomes, despite decades of use.
Compare C1-INH with pathway-specific inhibitors: Use C1s inhibitor (from complement drug development pipelines) vs. global C1-INH. If C1-INH's effects on plaque are superior to C1s inhibition alone, non-C1 targets are responsible. This isolates the classical pathway contribution.
Additionally, measure C3a and C5a levels in plaque tissue to confirm complement consumption is specifically classical pathway-dependent.
The therapeutic angle is attractive but the mechanistic basis is underspecified. C1-INH's pleiotropic effects complicate interpretation.
---
| Hypothesis | Original Confidence | Revised Confidence | Primary Issue |
|------------|--------------------|--------------------|---------------|
| 1: Efferocytosis | 0.75 | 0.52 | Inverts known physiological role |
| 2: NLRP3 | 0.72 | 0.58 | Non-standard priming; redundant activators |
| 3: Neovascularization | 0.68 | 0.54 | Receptor ambiguity; VEGF claim inconsistency |
| 4: Foam cell formation | 0.70 | 0.56 | Receptor model incomplete; alternative interpretations |
| 5: NETosis | 0.65 | 0.48 | Wrong tissue context; redundant stimuli |
| 6: Neurodegeneration | 0.58 | 0.40 | Longest causal chain; model mismatch |
| 7: C1-INH repurposing | 0.62 | 0.55 | Off-target effects; timing issues |
---
The SKEPTIC's critical evaluation substantially deflates confidence across all seven hypotheses. After removing inflated claims, two hypotheses warrant serious translational consideration (H1 and H2, both borderline ~0.52-0.58), while the remainder face significant druggability, model system, or causal chain validity challenges. The fundamental unresolved question—whether C1Q is a causal driver or a compensatory biomarker—must be answered before resource-intensive drug development.
---
Revised Confidence: 0.52
| Aspect | Assessment |
|--------|------------|
| Target | C1S enzymatic activity (classical pathway convertase) |
| Existing inhibitors | C1s inhibitors in complement pipeline; no approved selective C1s inhibitor |
| Structural tractability | C1S is a serine protease with well-characterized active site—druggable |
| Penetration | Systemically bioavailable small molecules feasible |
| Challenge | Achieving sufficient local plaque concentrations while sparing systemic complement for immune surveillance |
Lead compounds: C1s inhibitors from Apitope, Roche, and Alexion pipelines.orfingutasanib (C1s inhibitor) has been in Phase I for autoimmune disease. No atherosclerosis-specific development.
| Model System | Validation Status |
|--------------|-------------------|
| C1qa−/− mice | Widely available; critical for mechanistic dissection |
| LDLR−/−C1qa−/− double KO | Directly tests hypothesis; achievable in 12-18 months |
| Intravital microscopy | Gold standard for efferocytosis kinetics; available at specialized centers |
| Necrotic core quantification | Oil Red O/hematoxylin-eosin morphometry—well-established |
| Human validation | C1Q/C1S expression in plaque RNA-seq datasets (GTEx, human atherosclerotic tissue archives) |
Critical biomarker gap: No circulating biomarker specifically tracks plaque efferocytosis efficiency. LDL-C, CRP, and Lp(a) are disease progression markers, not mechanistic readouts.
| Constraint | Impact |
|------------|--------|
| Patient population | Established atherosclerosis (secondary prevention)—regulatory path exists |
| Endpoint selection | IVUS/OCT-measured plaque volume is accepted surrogate; necrotic core imaging requires advanced MRI/PET |
| Duration | 2-3 year trials for plaque regression endpoints |
| Biomarker strategy | C1S activity assays in plasma (requires validation); IL-6/C1Q as pharmacodynamic markers |
| Regulatory precedent | No approved complement inhibitor for atherosclerosis (vs. eculizumab for PNH/aHUS) |
Key regulatory question: Would FDA require cardiovascular outcome trials (CVOT) given PCSK9 inhibitor precedent, or accept plaque imaging surrogates?
| Risk | Mitigation Strategy |
|------|---------------------|
| Systemic complement deficiency | Local (intravascular) delivery? Topical plaque targeting? |
| Infection susceptibility | C1S inhibition may increase encapsulated bacterial infection risk (meningococcal prophylaxis required for eculizumab) |
| Impaired homeostatic efferocytosis | Paradoxical: blocking C1Q-mediated clearance may worsen lesional debris |
| Off-target serine proteases | Selectivity profiling essential |
Safety profile of comparators: Eculizumab carries 1-2% meningococcal infection rate; similar concerns expected for C1S inhibitors.
| Phase | Timeline | Estimated Cost |
|-------|----------|----------------|
| Target validation (C1qa−/− × LDLR−/− studies) | 12-18 months | $200-400K |
| Lead optimization/ADME | 18-24 months | $1-3M |
| IND-enabling toxicology | 12 months | $2-4M |
| Phase I (safety/bioavailability) | 12-18 months | $5-10M |
| Phase II (plaque imaging endpoint) | 24-36 months | $15-30M |
| Phase III (CVOT) | 48-60 months | $100-200M |
Total realistic timeline: 7-10 years from target validation to potential approval.
Major cost driver: CVOT requirement if regulatory precedent requires cardiovascular outcome data.
---
Revised Confidence: 0.58
| Aspect | Assessment |
|--------|------------|
| Multi-target approach | Requires C1Q blockade + Syk inhibition (or NLRP3 inhibition) |
| Syk inhibitors | Fostamatinib (Tavalisse) approved for ITP—established oral bioavailability and safety |
| C1Q blockade | No selective C1Q inhibitors; monoclonal antibodies under development |
| NLRP3 inhibitors | MCC950 (research tool only); dapansutrile (Phase II for gout/CV disease) |
| Challenge | Dual targeting adds complexity; C1Q roles in immunity may limit complete blockade |
Strategic angle: Test fostamatinib (approved, safe) in atherosclerosis models first to determine Syk dependence. This repurposing path is faster than novel C1Q inhibitor development.
| Model System | Validation Status |
|--------------|-------------------|
| C1qa−/−Nlrp3−/−LDLR−/− triple KO | Directly tests epistasis; achievable with current mouse genetics |
| FLICA caspase-1 flow cytometry | Quantifies active inflammasome in plaque CD45+CD68+ cells |
| scRNA-seq of lesional macrophages | Established methodology; captures inflammasome signature |
| Human biomarkers | Plasma IL-1β, IL-18, C1Q protein (ELISA); caspase-1 activity assays |
| Translation readiness | IL-1β-targeted therapies (anakinra, canakinumab) have established atherosclerosis biomarker programs |
Advantage: Can leverage CANTOS trial (canakinumab) precedent for IL-1β pathway validation in atherosclerosis.
| Constraint | Impact |
|------------|--------|
| Patient population | Secondary prevention after ACS (CANTOS precedent) |
| Regulatory precedent | Canakinumab approved for cardiovascular risk reduction (IL-1β pathway) |
| Endpoint selection | hsCRP reduction as PD marker; MACE as clinical endpoint |
| Biomarker strategy | hsCRP, IL-6, IL-1β as pharmacodynamic markers—well-validated |
| Combination approach | C1Q + Syk blockade requires separate development or fixed-dose combination |
Regulatory advantage: The IL-1β axis is validated; adding C1Q/Syk component may be seen as mechanistic refinement rather than novel indication.
| Risk | Mitigation Strategy |
|------|---------------------|
| Syk inhibition | Fostamatinib has hypertension, hepatotoxicity, neutropenia warnings |
| NLRP3 inhibition | Potential immune suppression (infection risk); unclear impact on protective inflammasome functions |
| C1Q blockade | Unknown; complement deficiency increases infection/autoimmune risk |
| Off-target effects | Fostamatinib has off-target VEGFR inhibition |
Comparative safety: Canakinumab has excellent safety profile (CANTOS: no increased serious infections at 150mg). Syk + C1Q combination may be less safe.
| Phase | Timeline | Estimated Cost |
|-------|----------|----------------|
| Fostamatinib repurposing studies | 12-18 months (mouse models) | $300-500K |
| Fostamatinib Phase II in atherosclerosis | 18-24 months | $10-20M |
| C1Q antibody development | 36-48 months | $20-40M |
| Combination therapy IND | 12 months | $3-5M |
| Phase III (if single-agent successful) | 36-48 months | $80-150M |
Accelerated path: Fostamatinib is already approved; a Phase II atherosclerosis trial could start within 2 years if preclinical data support. This is the fastest route to proof-of-concept.
Total realistic timeline: 5-7 years (fostamatinib alone) or 8-10 years (novel C1Q antibody + fostamatinib combination).
---
Revised Confidence: 0.54
| Aspect | Assessment |
|--------|------------|
| Target | gC1qR/p33 on endothelium (receptor) + C1Q ligand |
| gC1qR antagonists | Peptide antagonists exist (p33-derived peptides); not drug-like |
| C1Q neutralizing antibodies | None approved; research-grade antibodies available |
| CD91 (LRP1) antagonists | RAP (receptor-associated protein) is research tool only |
| Challenge | Receptor is widely expressed; systemic blockade may cause off-target angiogenesis effects |
Lead candidates: No tractable drug-like small molecules. Antibody approach is most feasible but requires significant investment.
| Model System | Validation Status |
|--------------|-------------------|
| Corneal micropocket assay | Gold standard for angiogenesis; technically demanding |
| Aortic ring assay | Ex vivo angiogenesis; widely used |
| Endothelial tube formation | In vitro screening assay; well-established |
| Intraplaque hemorrhage quantification | Carboxyhemoglobin, CD31+ extravasation—validated in mice |
| Human validation | C1Q expression in unstable vs. stable plaque (IHC); correlation with vasa vasorum density |
Critical biomarker gap: No circulating angiogenic marker specific to plaque neovascularization.
| Constraint | Impact |
|------------|--------|
| Patient population | Advanced atherosclerosis with plaque vulnerability—not established clinical indication |
| Endpoint selection | Intraplaque hemorrhage on MRI is emerging but not regulatory-accepted surrogate |
| Imaging requirements | USPIO-MRI, PET with angiogenesis tracers—costly, limited centers |
| Regulatory precedent | No approved anti-angiogenic for atherosclerosis |
Strategic question: Would FDA approve an indication for "plaque stabilization" without established clinical outcome benefits?
| Risk | Mitigation Strategy |
|------|---------------------|
| Systemic angiogenesis inhibition | Wound healing, menstrual cycle, coronary collaterals—all require angiogenesis |
| gC1qR is widely expressed | Potential off-target effects in multiple tissues |
| Plaque hemorrhage paradox | Reducing neovascularization may stabilize plaques but could impair healing |
Comparative safety: Anti-VEGF agents (bevacizumab) have hypertension, proteinuria, bleeding, impaired wound healing.
| Phase | Timeline | Estimated Cost |
|-------|----------|----------------|
| Receptor characterization | 12-18 months | $300-500K |
| Antibody development | 24-36 months | $5-10M |
| Preclinical efficacy | 18-24 months | $2-4M |
| IND-enabling studies | 12 months | $3-5M |
| Phase I/II | 24-36 months | $20-40M |
Total realistic timeline: 7-9 years from target validation to Phase II completion.
Verdict: Lower priority than H1/H2 due to druggability challenges and regulatory uncertainty.
---
Revised Confidence: 0.56
| Aspect | Assessment |
|--------|------------|
| Target | CD91 (LRP1) on macrophages; SR-A (MSR1) and CD36 |
| CD36 inhibitors | Multiple CD36 antagonists in development; some in preclinical/Phase I |
| SR-A inhibitors | Less advanced; targeting MSR1 is more challenging |
| C1Q-CD91 axis | No selective inhibitors; LRP1 modulators exist (Rapamycin, etc.) |
| Challenge | CD36 and SR-A are also involved in metabolic functions (fatty acid uptake, insulin signaling) |
Lead candidates: Several CD36 monoclonal antibodies in development for metabolic/nflammatory diseases.
| Model System | Validation Status |
|--------------|-------------------|
| MSR1−/−CD36−/− double KO mice | Widely available |
| C1qa−/−BMDM with recombinant C1Q | Definitive epistasis test |
| Oil red O quantification | Standard foam cell assay |
| Human foam cell model | THP-1 and primary monocyte-derived macrophages—translatable |
| Biomarkers | Plasma oxLDL, Lp(a), cholesterol efflux capacity |
Advantage: Human macrophage system is directly relevant; foam cell formation is well-characterized.
| Constraint | Impact |
|------------|--------|
| Patient population | Hypercholesterolemia/dyslipidemia; established regulatory pathway |
| Endpoint selection | LDL-C reduction (established); plaque imaging as secondary |
| Biomarker strategy | Cholesterol efflux capacity, plasma oxLDL as PD markers |
| Regulatory precedent | PCSK9 inhibitors, statins—lipid-lowering pathway is well-established |
Strategic question: Is blocking the C1Q-CD36 axis more effective than established lipid-lowering therapies?
| Risk | Mitigation Strategy |
|------|---------------------|
| CD36 deficiency | Impaired fatty acid uptake, insulin resistance, altered taste (in CD36-deficient humans) |
| SR-A deficiency | Altered lipid metabolism, autoimmune phenotypes |
| Metabolic disruption | Targeting macrophage lipid uptake may cause systemic metabolic dysfunction |
| Alternative clearance blocked | May impair reverse cholesterol transport |
Comparative risk: CD36 is a non-essential receptor but has important metabolic roles. Complete blockade is likely unsafe; partial inhibition may be insufficient.
| Phase | Timeline | Estimated Cost |
|-------|----------|----------------|
| Target validation | 12-18 months | $200-400K |
| Lead optimization | 18-24 months | $2-4M |
| Preclinical/IND | 12-18 months | $3-5M |
| Phase I (safety/metabolic endpoints) | 12-18 months | $5-10M |
| Phase II/III | 36-48 months | $50-100M |
Total realistic timeline: 6-8 years.
Verdict: Moderate feasibility, but safety concerns around metabolic disruption are substantial. Lipid-lowering therapies are more proven and safer.
---
Revised Confidence: 0.48
| Aspect | Assessment |
|--------|------------|
| Target | PAD4 enzyme (NETosis executor) |
| PAD4 inhibitors | Multiple compounds in preclinical development; GSK484 (research tool) |
| C1Q-NET axis | No selective blockers; would require dual targeting |
| Challenge | PAD4 is intracellular; drug penetration required |
Lead candidates: PAD4 inhibitors from GlaxoSmithKline, University of Texas; no clinical-stage compounds yet.
| Model System | Validation Status |
|--------------|-------------------|
| NET quantification | CitH3, MPO-DNA ELISA, neutrophil elastase-DNA complexes—validated |
| Intravital microscopy | Direct visualization of plaque NETs |
| PAD4−/− mice | Available; used in atherosclerosis studies |
| Human validation | Plasma NET markers in ACS patients—established |
**
{"ranked_hypotheses":[{"title":"C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages","description":"C1Q binding to modified LDL particles triggers Syk kinase signaling and mitochondrial ROS production, providing a priming signal for NLRP3 inflammasome assembly in lesional macrophages. This mechanism creates a feed-forward inflammatory loop where C1Q-opsonized cholesterol crystals activate caspase-1, driving IL-1β/IL-18 secretion and perpetuating plaque inflammation. The hypothesis leverages the CANTOS trial precedent for IL-1β-targeted therapy in atherosclerosis, offering a clear translational path via repurposing the Syk inhibitor fostamatinib.","target_gene":"C1QA/C1QC","dimension_scores":{"evidence_strength":0.65,"novelty":0.58,"feasibility":0.72,"therapeutic_potential":0.68,"mechanistic_plausibility":0.60,"druggability":0.65,"safety_profile":0.55,"competitive_landscape":0.62,"data_availability":0.70,"reproducibility":0.60},"composite_score":0.64,"evidence_for":[{"claim":"Syk kinase links complement activation to NLRP3 inflammasome signaling","pmid":"19370150"},{"claim":"Cholesterol crystals activate NLRP3 inflammasome in atherosclerotic macrophages","pmid":"20393552"},{"claim":"C1Q induces mitochondrial ROS in macrophages providing second signal","pmid":"30396994"},{"claim":"IL-1β pathway validated in CANTOS cardiovascular outcomes trial","pmid":"28903622"}],"evidence_against":[{"claim":"Cholesterol crystals alone are sufficient for NLRP3 activation without C1Q","pmid":"20393552"},{"claim":"NLRP3, ASC, IL-1β deficiency shows only modest 20-30% lesion reduction","pmid":"NA - general NLRP3 KO literature"},{"claim":"C1Q positioning as signal 1 for NLRP3 priming is non-standard","pmid":"NA - mechanistic critique"}]},{"title":"C1Q-Induced Foam Cell Formation via Scavenger Receptor Upregulation","description":"C1Q binding to macrophages via CD91/TLR2 heterodimers triggers NF-κB and STAT1 signaling, upregulating SR-A and CD36 scavenger receptors. This creates a feed-forward loop where C1Q-opsonized oxLDL internalization drives foam cell formation, which subsequently produces more C1Q. The mechanism connects the biomarker finding directly to disease progression and offers multiple druggable nodes (CD91, SR-A, CD36).","target_gene":"C1QA/C1QC","dimension_scores":{"evidence_strength":0.58,"novelty":0.62,"feasibility":0.70,"therapeutic_potential":0.72,"mechanistic_plausibility":0.55,"druggability":0.62,"safety_profile":0.48,"competitive_landscape":0.60,"data_availability":0.65,"reproducibility":0.55},"composite_score":0.62,"evidence_for":[{"claim":"C1Q enhances LDL uptake by monocytes","pmid":"15488903"},{"claim":"C1Q modulates macrophage TLR signaling through CD91/TLR2 crosstalk","pmid":"33585041"},{"claim":"CD36 contributes to foam cell formation and atherosclerosis","pmid":"17110344"},{"claim":"SR-A and CD36 are established foam cell markers with therapeutic relevance","pmid":"Multiple established"}],"evidence_against":[{"claim":"C1Q binding to TLR2/6 is not well-established; C1Q canonically engages calreticulin/CD91 or gC1qR","pmid":"NA - mechanistic critique"},{"claim":"C1Q could represent compensatory enhanced cholesterol clearance rather than pathological drive","pmid":"NA - alternative interpretation"},{"claim":"SR-A and CD36 are upregulated by oxLDL via PPARγ/LXR independent of C1Q","pmid":"Multiple established"}]},{"title":"C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion","description":"Chronic hyperactivation of classical complement in the atherosclerotic intima leads to C1S-mediated opsonization of late apoptotic foam cells, but paradoxically blocks efficient clearance. C5b-9 membrane attack complex deposition on surviving cells causes secondary necrosis, releasing cholesterol crystals and DAMPs that amplify local inflammation and expand the necrotic core. The hypothesis requires C1Q to 'flip' from its known homeostatic role to pathological at high lesional concentrations.","target_gene":"C1QA/C1QC","dimension_scores":{"evidence_strength":0.55,"novelty":0.55,"feasibility":0.68,"therapeutic_potential":0.65,"mechanistic_plausibility":0.50,"druggability":0.60,"safety_profile":0.52,"competitive_landscape":0.58,"data_availability":0.60,"reproducibility":0.55},"composite_score":0.60,"evidence_for":[{"claim":"Botto M et al. establishes C1q role in apoptotic cell clearance","pmid":"16205503"},{"claim":"C1q binds apoptotic cells via calreticulin/CD91","pmid":"24639361"},{"claim":"Defective efferocytosis promotes necrotic core formation in murine atherosclerosis","pmid":"19841018"},{"claim":"C1S inhibitors exist in complement drug development pipelines","pmid":"Multiple pharmaceutical sources"}],"evidence_against":[{"claim":"C1Q is canonically a promoter of efferocytosis, not an inhibitor - hypothesis inverts known role","pmid":"16205503"},{"claim":"C1Q deficiency causes defective clearance and autoimmunity, opposite direction","pmid":"16205503"},{"claim":"C1q-/- mice on hypercholesterolemic backgrounds have not consistently shown protection","pmid":"NA - implicit falsification"},{"claim":"Mechanistic threshold model for C1Q 'flip' not proposed","pmid":"NA - mechanistic gap"}]},{"title":"C1Q-Angiogenic Axis Promoting Plaque Neovascularization","description":"Macrophage-secreted C1Q binds to endothelial gC1qR/CD91 receptors, activating src/FAK/ERK1/2 signaling to upregulate VEGFR2 and promote VEGF-independent angiogenesis. This drives unstable microvessel formation prone to hemorrhage, contributing to plaque progression and vulnerability. The hypothesis connects lesional macrophage infiltration to intraplaque hemorrhage and clinical instability.","target_gene":"C1QA/C1QC","dimension_scores":{"evidence_strength":0.55,"novelty":0.60,"feasibility":0.55,"therapeutic_potential":0.58,"mechanistic_plausibility":0.52,"druggability":0.42,"safety_profile":0.45,"competitive_landscape":0.52,"data_availability":0.58,"reproducibility":0.50},"composite_score":0.53,"evidence_for":[{"claim":"C1Q induces angiogenic program in endothelial cells independent of VEGF","pmid":"24453254"},{"claim":"gC1qR identified as C1Q receptor on endothelium","pmid":"8006586"},{"claim":"Neovascularization correlates with plaque instability in human atherosclerosis","pmid":"12403663"},{"claim":"Angiogenesis is clinically validated as therapeutic target for plaque stabilization","pmid":"Multiple established"}],"evidence_against":[{"claim":"gC1qR is a widely expressed chaperone, not a canonical signaling receptor","pmid":"NA - mechanistic critique"},{"claim":"VEGF independence claim contradicts stated VEGFR2 upregulation mechanism","pmid":"NA - internal inconsistency"},{"claim":"No direct evidence links C1Q to intraplaque hemorrhage","pmid":"NA - translational gap"},{"claim":"No drug-like small molecules targeting gC1qR available","pmid":"NA - druggability challenge"}]},{"title":"Therapeutic Repurposing: C1-INH as Plaque-Stabilizing Agent","description":"Recombinant C1-esterase inhibitor (Ruconest) blocks C1R/C1S proteolytic activity, preventing classical pathway activation without affecting lectin or alternative pathways. This reduces opsonization of apoptotic cells, C5b-9 formation, and downstream inflammatory cytokine production, promoting a more stable plaque phenotype. The hypothesis leverages an already-approved biologic with established safety data.","target_gene":"C1R/C1S","dimension_scores":{"evidence_strength":0.52,"novelty":0.48,"feasibility":0.58,"therapeutic_potential":0.62,"mechanistic_plausibility":0.52,"druggability":0.58,"safety_profile":0.50,"competitive_landscape":0.55,"data_availability":0.55,"reproducibility":0.52},"composite_score":0.53,"evidence_for":[{"claim":"C1-INH mechanism and clinical use established for hereditary angioedema","pmid":"18692500"},{"claim":"C1-INH reduces inflammation in ischemia-reperfusion models","pmid":"34712720"},{"claim":"C1Q identified as atherosclerosis risk gene in index paper","pmid":"38179058"},{"claim":"C1-INH is FDA-approved with established safety profile","pmid":"Multiple regulatory sources"}],"evidence_against":[{"claim":"C1-INH has broad effects beyond C1R/C1S (kallikrein, FXIIa, plasmin)","pmid":"18692500"},{"claim":"Classical pathway blockade may shunt activation to lectin/alternative pathways","pmid":"NA - compensatory mechanism"},{"claim":"Hereditary angioedema patients on C1-INH lack reported atherosclerosis outcomes","pmid":"NA - clinical data gap"},{"claim":"Acute 8-week administration may not model decades-long human disease development","pmid":"NA - temporal mismatch"}]},{"title":"NETosis Amplification by C1Q in Plaque Neutrophils","description":"C1Q serves as a neutrophil chemoattractant and potentiates NETosis in response to cholesterol crystals. C1Q-opsonized NETs become nidus for C3b/iC3b deposition, recruiting additional immune cells and forming immune complexes that perpetuate plaque inflammation. This links neutrophil recruitment to complement amplification and plaque progression.","target_gene":"C1QA/C1QC","dimension_scores":{"evidence_strength":0.45,"novelty":0.55,"feasibility":0.52,"therapeutic_potential":0.50,"mechanistic_plausibility":0.45,"druggability":0.50,"safety_profile":0.48,"competitive_landscape":0.52,"data_availability":0.50,"reproducibility":0.48},"composite_score":0.50,"evidence_for":[{"claim":"C1Q promotes NETosis in neurological disease models","pmid":"34620133"},{"claim":"NETs accelerate atherosclerotic plaque progression","pmid":"31740993"},{"claim":"C1Q-coated structures enhance complement activation cascades","pmid":"35294448"},{"claim":"PAD4 inhibitors in preclinical development for NETosis-targeted therapy","pmid":"Multiple pharmaceutical sources"}],"evidence_against":[{"claim":"Primary citation is neuroinflammation context - neutrophils in brain differ from plaque","pmid":"34620133"},{"claim":"C5aR-like receptor for C1Q on neutrophils hypothesized but not identified","pmid":"NA - receptor identification gap"},{"claim":"Cholesterol crystals alone potently induce NETosis; C1Q contribution unclear","pmid":"Multiple established"},{"claim":"NETs predominantly in early-to-mid lesions; C1Q more associated with advanced plaques","pmid":"NA - temporal mismatch"}]},{"title":"C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis","description":"Atherosclerotic inflammation increases circulating IL-6 that crosses the compromised blood-brain barrier, priming cerebral endothelial cells to express C1Q. Brain microglia upregulate C1QC in response, driving complement-mediated synaptic pruning and cognitive decline. This mechanistic chain connects peripheral C1Q-driven atherosclerosis severity to neurodegeneration and vascular dementia.","target_gene":"C1QA/C1QC","dimension_scores":{"evidence_strength":0.40,"novelty":0.70,"feasibility":0.42,"therapeutic_potential":0.52,"mechanistic_plausibility":0.38,"druggability":0.40,"safety_profile":0.42,"competitive_landscape":0.48,"data_availability":0.45,"reproducibility":0.40},"composite_score":0.47,"evidence_for":[{"claim":"Systemic complement activation links to neuroinflammation","pmid":"24107782"},{"claim":"C1Q mediates synapse loss in neurodegeneration models","pmid":"32393358"},{"claim":"Cardiovascular risk drives microglial activation","pmid":"36218221"},{"claim":"C1Q involved in developmental synaptic pruning - disease relevance plausible","pmid":"Multiple established"}],"evidence_against":[{"claim":"Causal chain contains at least 4 unproven steps","pmid":"NA - mechanistic critique"},{"claim":"IL-6 crossing BBB is context-dependent; sufficiency unproven","pmid":"NA - BBB assumption critique"},{"claim":"CADASIL (NOTCH3mut) cross is mechanistically inappropriate for atherosclerosis","pmid":"NA - model mismatch"},{"claim":"C1Q expression patterns differ between mice and humans in CNS","pmid":"Multiple species comparison studies"},{"claim":"Longest causal chain with weakest direct evidence for atherosclerosis","pmid":"NA - synthesis critique"}]}],"knowledge_edges":[{"source_id":"H1_Efferocytosis","source_type":"hypothesis","target_id":"C1QA","target_type":"gene","relation":"proposes_pathological_role_in"},{"source_id":"H1_Efferocytosis","source_type":"hypothesis","target_id":"C1S","target_type":"gene","relation":"mechanistic_intermediate_for"},{"source_id":"H1_Efferocytosis","source_type":"hypothesis","target_id":"C5B9","target_type":"complex","relation":"downstream_effector_of"},{"source_id":"H2_NLRP3","source_type":"hypothesis","target_id":"C1QA","target_type":"gene","relation":"priming_signal_from"},{"source_id":"H2_NLRP3","source_type":"hypothesis","target_id":"SYK","target_type":"kinase","relation":"signaling_intermediate_of"},{"source_id":"H2_NLRP3","source_type":"hypothesis","target_id":"NLRP3","target_type":"inflammasome","relation":"activates_inflammasome"},{"source_id":"H2_NLRP3","source_type":"hypothesis","target_id":"IL1B","target_type":"cytokine","relation":"upstream_regulator_of"},{"source_id":"H3_Angiogenesis","source_type":"hypothesis","target_id":"C1QA","target_type":"gene","relation":"ligand_source_of"},{"source_id":"H3_Angiogenesis","source_type":"hypothesis","target_id":"GPIBA","target_type":"receptor","relation":"receptor_for"},{"source_id":"H3_Angiogenesis","source_type":"hypothesis","target_id":"VEGFR2","target_type":"receptor","relation":"upregulated_by"},{"source_id":"H4_FoamCell","source_type":"hypothesis","target_id":"C1QA","target_type":"gene","relation":"autocrine_prime_by"},{"source_id":"H4_FoamCell","source_type":"hypothesis","target_id":"CD91","target_type":"receptor","relation":"receptor_for"},{"source_id":"H4_FoamCell","source_type":"hypothesis","target_id":"CD36","target_type":"receptor","relation":"upregulates"},{"source_id":"H4_FoamCell","source_type":"hypothesis","target_id":"MSR1","target_type":"receptor","relation":"upregulates"},{"source_id":"H5_NETosis","source_type":"hypothesis","target_id":"C1QA","target_type":"gene","relation":"amplifies"},{"source_id":"H5_NETosis","source_type":"hypothesis","target_id":"PAD4","target_type":"enzyme","relation":"activates"},{"source_id":"H6_Neurodegeneration","source_type":"hypothesis","target_id":"C1QA","target_type":"gene","relation":"systemic_driver_of"},{"source_id":"H6_Neurodegeneration","source_type":"hypothesis","target_id":"IL6","target_type":"cytokine","relation":"intermediate_mediator_of"},{"source_id":"H6_Neurodegeneration","source_type":"hypothesis","target_id":"C1QC","target_type":"gene","relation":"upregulated_in_microglia"},{"source_id":"H7_C1INH","source_type":"hypothesis","target_id":"C1R","target_type":"protease","relation":"inhibits"},{"source_id":"H7_C1INH","source_type":"hypothesis","target_id":"C1S","target_type":"protease","relation":"inhibits"},{"source_id":"H7_C1INH","source_type":"hypothesis","target_id":"C1QA","target_type":"gene","relation":"blocks_activation_of"},{"source_id":"H2_NLRP3","source_type":"hypothesis","target_id":"H4_FoamCell","target_type":"hypothesis","relation":"shares_nfkb_pathway_with"},{"source_id":"H2_NLRP3","source_type":"hypothesis","target_id":"H1_Efferocytosis","target_type":"hypothesis","relation":"converges_on_il1b_with"},{"source_id":"H3_Angiogenesis","source_type":"hypothesis","target_id":"H1_Efferocytosis","target_type":"hypothesis","relation":"both_contribute_to_plaque_destabilization"},{"source_id":"Source_Paper","source_type":"publication","target_id":"C1QA","target_type":"gene","relation":"identifies_as_risk_gene"},{"source_id":"Source_Paper","source_type":"publication","target_id":"C1QC","target_type":"gene","relation":"identifies_as_risk_gene"}],"synthesis_summary":"The integration of therapeutic, skeptical, and feasibility perspectives identifies the C1Q-triggered NLRP3 inflammasome hypothesis (composite score 0.64) and C1Q-induced foam cell formation hypothesis (0.62) as the top-ranked priorities for mechanistic investigation and therapeutic development. The NLRP3 axis benefits from the strongest translational precedent (CANTOS trial validation of IL-1β targeting in cardiovascular disease) and an immediate repurposing opportunity via the FDA-approved Syk inhibitor fostamatinib, with the triple knockout C1qa−/−Nlrp3−/−LDLR−/− mouse representing the critical falsifying experiment. The foam cell hypothesis offers a more direct connection between the biomarker finding and disease progression, with multiple druggable nodes (CD91, SR-A, CD36), though safety concerns around metabolic disruption require careful evaluation. The efferocytosis hypothesis, while mechanistically compelling, is undermined by its inversion of C1Q's known physiological role and lack of direct C1Q-atherosclerosis data; the fundamental unresolved question—whether C1Q serves as a causal driver or a compensatory biomarker of complement-consuming inflammation—must be addressed via C1q−/− mouse experiments on hypercholesterolemic backgrounds before substantial resource commitment to any hypothesis. Hypotheses 5-7 (NETosis, neurodegeneration, C1-INH repurposing) represent lower priority targets given weaker direct evidence, longer causal chains, or significant druggability/regulatory challenges, though the C1-INH path offers an accelerated repurposing route given existing FDA approval for hereditary angioedema."}